Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia
Conditions
Brief summary
This phase I/II trial studies the side effects and best dose of decitabine followed by mitoxantrone hydrochloride, etoposide, and cytarabine and to see how well they work in treating patients with acute myeloid leukemia or high-risk myelodysplastic syndrome that has returned after a period of improvement or does not respond to treatment. Drugs used in chemotherapy, such as mitoxantrone hydrochloride, etoposide, cytarabine, and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more cancer cells.
Detailed description
PRIMARY OBJECTIVES: I. Estimate the maximum tolerated dose (MTD) of decitabine priming followed by sequential mitoxantrone hydrochloride/etoposide/cytarabine (MEC) chemotherapy in adults with relapsed/refractory acute myeloid leukemia (AML). SECONDARY OBJECTIVES: I. Determine, within the limits of a Phase 1/2 study, disease response and duration of remission. II. Identify biomarkers (e.g., deoxyribonucleic acid \[DNA\] methylation and/or gene expression changes) associated with treatment responses. OUTLINE: This is a phase I, dose-escalation study of decitabine followed by a phase II study. Patients receive decitabine intravenously (IV) on days -9 to -5 (dose level 1), days -11 to -5 (dose level 2), or days -14 to -5 (dose level 3). INDUCTION THERAPY: Patients receive mitoxantrone hydrochloride IV on days 1-5, etoposide IV on days 1-5, and cytarabine IV on days 1-5. Patients achieving complete response (CR) or CR with incomplete platelet count recovery (CRp) may receive up to 2 courses of induction therapy and up to 2 courses of consolidation therapy. After completion of study treatment, patients are followed up every 3 months for up to 5 years.
Interventions
DRUGCytarabine
Given IV
DRUGDecitabine
Given IV
DRUGEtoposide
Given IV
OTHERLaboratory Biomarker Analysis
Correlative studies
DRUGMitoxantrone Hydrochloride
Given IV
Sponsors
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Prior diagnosis of high-risk myelodysplastic syndrome (MDS) (\>= 10% blasts) or AML other than acute promyelocytic leukemia (APL) with t(15;17) (q22;q12) or variants according to the 2008 World Health Organization (WHO) classification; patients with biphenotypic AML are eligible * Relapsed/persistent disease according to standard criteria requiring salvage therapy; outside diagnostic material is acceptable as long as peripheral blood and/or bone marrow slides are reviewed at the study institution; flow cytometric analysis of peripheral blood and/or bone marrow should be performed according to institutional practice guidelines * Patients with prior autologous or allogeneic hematopoietic cell transplantation (HCT) are eligible if relapse occurs provided symptoms of graft-versus host disease are well controlled with stable use of immunosuppressive agents * Treatment-related mortality (TRM) score =\< 9.2 as calculated with simplified model * Should be off any active therapy for AML with the exception of hydroxyurea for at least 14 days prior to study registration unless patient has rapidly progressive disease, and all grade 2-4 non-hematologic toxicities should have resolved * May have previously received monotherapy with demethylating agents for MDS or AML * May have previously received chemotherapy with MEC for MDS or AML * Patients with symptoms/signs of hyperleukocytosis or white blood cells (WBC) \> 100,000/uL can be treated with leukapheresis or may receive up to 2 doses of cytarabine (up to 500 mg/m\^2/dose) prior to enrollment * Bilirubin =\< 2 x institutional upper limit of normal (IULN) unless elevation is thought to be due to hepatic infiltration by AML, Gilbert's syndrome, or hemolysis (assessed within 7 days prior to study day 1) * Serum creatinine =\< 1.5 x IULN (assessed within 7 days prior to study day 1) * Left ventricular ejection fraction \>= 40%, assessed within 3 months prior to study day 1, e.g. by multi gated acquisition (MUGA) scan or echocardiography, or other appropriate diagnostic modality and no clinical evidence of congestive heart failure; if the patient had anthracycline-based therapy since the most recent cardiac assessment, cardiac evaluation should be repeated if there is clinical or radiographical suspicion of cardiac dysfunction, or if the previous cardiac assessment was abnormal * Women of childbearing potential and men must agree to use adequate contraception * Provide written informed consent
Exclusion criteria
* Refractory/relapsing myeloid blast crisis of chronic myeloid leukemia (CML), unless patient is not considered candidate for tyrosine kinase inhibitor treatment * Concomitant illness associated with a likely survival of \< 1 year * Active systemic fungal, bacterial, viral, or other infection, unless disease is under treatment with anti-microbials and/or controlled or stable (e.g. if specific, effective therapy is not available/feasible or desired \[e.g. chronic viral hepatitis, human immunodeficiency virus (HIV)\]); patient needs to be clinically stable as defined as being afebrile and hemodynamically stable for 24 hours; patients with fever thought to be likely secondary to leukemia are eligible * Known hypersensitivity to any study drug * Pregnancy or lactation * Patients may not be receiving any other investigational agents
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Most Efficacious and Tolerated Dosage of Decitabine (Period 1) | through day 45 | MTD (most tolerated dose) of decitabine, measured in number of dose limiting toxicities. MTD defined as the highest dose in which the incidence of dose limiting toxicity is \< 33%, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Phase I) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Remission Rate Including CR and CRp | Up to 5 years | Complete remission (CR) and Complete remission with incomplete platelet recovery (CRp) categorized according to criteria recommended by International Working Groups: Complete resolution of disease-related symptoms and signs including palpable hepatosplenomegaly; hemoglobin level at least 110 g/L, platelet count at least 100x10\^9/L, and absolute neutrophil count at least 1.0 x10\^9/L. In addition, all 3 blood counts should be no higher than the upper normal limit; Normal leukocyte differential; Bone marrow histologic remission defined as the presence of age-adjusted normocellularity, no more than 5% myeloblasts, and an osteomyelofibrosis grade no higher than 1. |
| Duration of Relapse-free Survival (for Patients Achieving CR or CRp) | Up to 5 years | Categorized according to criteria recommended by International Working Groups. |
| Overall Survival | Up to 5 years | Survival measured as of day of last contact. Categorized according to criteria recommended by International Working Groups. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Dose Level 1: 5-Days of Decitabine-MEC Patients receive decitabine IV days -9 to -5 (dose level 1).
INDUCTION THERAPY: Patients receive mitoxantrone hydrochloride IV on days 1-5, etoposide IV on days 1-5, and cytarabine IV on days 1-5. Patients achieving CR or CR with CRp may receive up to 2 courses of induction therapy and up to 2 courses of consolidation therapy.
Cytarabine: Given IV
Decitabine: Given IV
Etoposide: Given IV
Laboratory Biomarker Analysis: Correlative studies
Mitoxantrone Hydrochloride: Given IV | 6 |
| Dose Level 2: 7-Days of Decitabine-MEC Patients receive decitabine IV days -11 to -5 (dose level 2).
INDUCTION THERAPY: Patients receive mitoxantrone hydrochloride IV on days 1-5, etoposide IV on days 1-5, and cytarabine IV on days 1-5. Patients achieving CR or CR with CRp may receive up to 2 courses of induction therapy and up to 2 courses of consolidation therapy.
Cytarabine: Given IV
Decitabine: Given IV
Etoposide: Given IV
Laboratory Biomarker Analysis: Correlative studies
Mitoxantrone Hydrochloride: Given IV | 34 |
| Dose Level 3: 10-Days of Decitabine-MEC Patients receive decitabine IV days -14 to -5 (dose level 3).
INDUCTION THERAPY: Patients receive mitoxantrone hydrochloride IV on days 1-5, etoposide IV on days 1-5, and cytarabine IV on days 1-5. Patients achieving CR or CR with CRp may receive up to 2 courses of induction therapy and up to 2 courses of consolidation therapy.
Cytarabine: Given IV
Decitabine: Given IV
Etoposide: Given IV
Laboratory Biomarker Analysis: Correlative studies
Mitoxantrone Hydrochloride: Given IV | 12 |
| Total | 52 |
Baseline characteristics
| Characteristic | Dose Level 1: 5-Days of Decitabine-MEC | Dose Level 2: 7-Days of Decitabine-MEC | Dose Level 3: 10-Days of Decitabine-MEC | Total |
|---|---|---|---|---|
| Age, Continuous | 54 years | 55 years | 57 years | 55 years |
| Sex: Female, Male Female | 1 Participants | 16 Participants | 6 Participants | 23 Participants |
| Sex: Female, Male Male | 5 Participants | 18 Participants | 6 Participants | 29 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 2 / 6 | 1 / 34 | 0 / 12 |
| other Total, other adverse events | 6 / 6 | 33 / 34 | 12 / 12 |
| serious Total, serious adverse events | 0 / 6 | 0 / 34 | 0 / 12 |
Outcome results
Primary
Most Efficacious and Tolerated Dosage of Decitabine (Period 1)
MTD (most tolerated dose) of decitabine, measured in number of dose limiting toxicities. MTD defined as the highest dose in which the incidence of dose limiting toxicity is \< 33%, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Phase I)
Time frame: through day 45
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dose Level 1: 5-Days of Decitabine-MEC | Most Efficacious and Tolerated Dosage of Decitabine (Period 1) | Complete Remission | 1 Incidents |
| Dose Level 1: 5-Days of Decitabine-MEC | Most Efficacious and Tolerated Dosage of Decitabine (Period 1) | Resistant Disease | 1 Incidents |
| Dose Level 1: 5-Days of Decitabine-MEC | Most Efficacious and Tolerated Dosage of Decitabine (Period 1) | Death (among those who received MEC) | 2 Incidents |
| Dose Level 1: 5-Days of Decitabine-MEC | Most Efficacious and Tolerated Dosage of Decitabine (Period 1) | Complete Remission, incomplete PLT recovery | 2 Incidents |
| Dose Level 1: 5-Days of Decitabine-MEC | Most Efficacious and Tolerated Dosage of Decitabine (Period 1) | Dose-limiting toxiticies | 0 Incidents |
| Dose Level 1: 5-Days of Decitabine-MEC | Most Efficacious and Tolerated Dosage of Decitabine (Period 1) | Complete Remission, incomplete blood count recover | 0 Incidents |
| Dose Level 1: 5-Days of Decitabine-MEC | Most Efficacious and Tolerated Dosage of Decitabine (Period 1) | Morphologic leukemia-free state | 0 Incidents |
| Dose Level 2: 7-Days of Decitabine-MEC | Most Efficacious and Tolerated Dosage of Decitabine (Period 1) | Morphologic leukemia-free state | 0 Incidents |
| Dose Level 2: 7-Days of Decitabine-MEC | Most Efficacious and Tolerated Dosage of Decitabine (Period 1) | Complete Remission, incomplete PLT recovery | 1 Incidents |
| Dose Level 2: 7-Days of Decitabine-MEC | Most Efficacious and Tolerated Dosage of Decitabine (Period 1) | Resistant Disease | 3 Incidents |
| Dose Level 2: 7-Days of Decitabine-MEC | Most Efficacious and Tolerated Dosage of Decitabine (Period 1) | Complete Remission | 5 Incidents |
| Dose Level 2: 7-Days of Decitabine-MEC | Most Efficacious and Tolerated Dosage of Decitabine (Period 1) | Complete Remission, incomplete blood count recover | 1 Incidents |
| Dose Level 2: 7-Days of Decitabine-MEC | Most Efficacious and Tolerated Dosage of Decitabine (Period 1) | Death (among those who received MEC) | 1 Incidents |
| Dose Level 2: 7-Days of Decitabine-MEC | Most Efficacious and Tolerated Dosage of Decitabine (Period 1) | Dose-limiting toxiticies | 0 Incidents |
| Dose Level 3: 10-Days of Decitabine-MEC | Most Efficacious and Tolerated Dosage of Decitabine (Period 1) | Death (among those who received MEC) | 0 Incidents |
| Dose Level 3: 10-Days of Decitabine-MEC | Most Efficacious and Tolerated Dosage of Decitabine (Period 1) | Dose-limiting toxiticies | 0 Incidents |
| Dose Level 3: 10-Days of Decitabine-MEC | Most Efficacious and Tolerated Dosage of Decitabine (Period 1) | Complete Remission | 3 Incidents |
| Dose Level 3: 10-Days of Decitabine-MEC | Most Efficacious and Tolerated Dosage of Decitabine (Period 1) | Complete Remission, incomplete PLT recovery | 2 Incidents |
| Dose Level 3: 10-Days of Decitabine-MEC | Most Efficacious and Tolerated Dosage of Decitabine (Period 1) | Morphologic leukemia-free state | 3 Incidents |
| Dose Level 3: 10-Days of Decitabine-MEC | Most Efficacious and Tolerated Dosage of Decitabine (Period 1) | Resistant Disease | 4 Incidents |
| Dose Level 3: 10-Days of Decitabine-MEC | Most Efficacious and Tolerated Dosage of Decitabine (Period 1) | Complete Remission, incomplete blood count recover | 0 Incidents |
Secondary
Duration of Relapse-free Survival (for Patients Achieving CR or CRp)
Categorized according to criteria recommended by International Working Groups.
Time frame: Up to 5 years
Population: Population includes all Dose Level 2 participants, from both periods 1 and 2, who achieved CR or CRp
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Dose Level 1: 5-Days of Decitabine-MEC | Duration of Relapse-free Survival (for Patients Achieving CR or CRp) | 150 Days |
Secondary
Overall Survival
Survival measured as of day of last contact. Categorized according to criteria recommended by International Working Groups.
Time frame: Up to 5 years
Population: Population includes all Dose Level 2 participants, from both periods 1 and 2.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Dose Level 1: 5-Days of Decitabine-MEC | Overall Survival | 564 days |
Secondary
Remission Rate Including CR and CRp
Complete remission (CR) and Complete remission with incomplete platelet recovery (CRp) categorized according to criteria recommended by International Working Groups: Complete resolution of disease-related symptoms and signs including palpable hepatosplenomegaly; hemoglobin level at least 110 g/L, platelet count at least 100x10\^9/L, and absolute neutrophil count at least 1.0 x10\^9/L. In addition, all 3 blood counts should be no higher than the upper normal limit; Normal leukocyte differential; Bone marrow histologic remission defined as the presence of age-adjusted normocellularity, no more than 5% myeloblasts, and an osteomyelofibrosis grade no higher than 1.
Time frame: Up to 5 years
Population: Population includes all Dose Level 2 participants from both periods 1 and 2.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Dose Level 1: 5-Days of Decitabine-MEC | Remission Rate Including CR and CRp | 11 Participants |